Last updated: February 26, 2026
Case Overview
Purdue Pharma L.P. filed a lawsuit against Alvogen Pine Brook LLC on December 9, 2015, in the U.S. District Court for the District of New Jersey. The case center around allegations of patent infringement related to opioid pharmaceutical formulations.
The core of Purdue's complaint involves claims that Alvogen's generic opioid products infringe on Purdue’s patents covering abuse-deterrent formulations of prescription opioids. This legal action aims to protect Purdue’s patent rights and maintain market exclusivity amidst generic competition.
Key Legal Issues
Patent Infringement and Validity
Purdue asserts that Alvogen’s generic formulations unlawfully infringe on patents held by Purdue. The patents in question include U.S. Patent Nos. 8,657,241 and 9,219,376, both covering abuse-deterrent formulations. Purdue claims these patents are valid, enforceable, and infringed by Alvogen’s generic versions.
Patent Term and Market Exclusivity
Purdue's primary concern centers on maintaining exclusivity for its abuse-deterrent opioid formulations, which it patents as a strategic defense against abuse and overdose. The litigation questions whether Alvogen’s products violate these protections, potentially disrupting Purdue’s patent rights.
Defenses and Challenges
Alvogen contends that Purdue’s patents are invalid for reasons including obviousness and lack of novelty. The defendant also challenges the scope of Purdue's patent claims, asserting that Alvogen's generic products do not infringe.
Case Development and Proceedings
Motion to Dismiss and Summary Judgment
- The case has seen motions from both sides, including Purdue’s motions to allege patent infringement and Alvogen’s motions to dismiss or invalidate Purdue’s patents.
- In 2016, Purdue filed a motion for a preliminary injunction to prevent Alvogen from launching its generic products during the litigation.
Court Rulings and Patent Interplay
- The court has considered motions for claim construction, which define the scope and interpretation of patent claims.
- In 2017, the district court denied Purdue’s preliminary injunction motion, citing insufficient proof of imminent harm and likelihood of success on patent infringement.
Patent Litigation Outcomes
- In 2018, the court ruled in favor of Alvogen on certain patent validity challenges, citing prior art references suggesting that Purdue’s patents could be deemed obvious.
- The case remains unresolved, with ongoing discovery and potential future rulings on the validity and infringement issues.
Market and Industry Impact
Patent Litigation in Opioid Space
This case exemplifies the legal battles over abuse-deterrent formulations, a critical aspect of the opioid market. Patent disputes influence the timing of generic entry, impacting drug prices and opioid distribution.
Strategic Implications
- Purdue’s focus on patent enforcement underscores its desire to shield its formulations from rapid generic competition.
- Alvogen’s defenses reflect a broader trend of generic manufacturers challenging patent validity to expedite market entry.
Policy Context
The litigation occurs amid heightened scrutiny of opioid manufacturers and regulatory concerns regarding abuse and overdose prevention. Patent strategies intersect with public health efforts and government regulation.
Financial and Business Impacts
While specific damages or settlement figures are unavailable publicly, patent infringement cases in this domain generally influence:
- Market share control for Purdue Pharma.
- Costs associated with litigation, including legal fees and potential licensing or settlement agreements.
- Future product development strategies focused on patent protection and formulations.
Summary of Legal Timeline
| Date |
Event |
Outcome/Notes |
| Dec 9, 2015 |
Complaint filed |
Purdue initiates patent infringement suit |
| 2016 |
Motion for preliminary injunction filed |
Denied in 2017 |
| 2017 |
Claim construction hearings |
Defined scope of patent claims |
| 2018 |
Court rules on patent validity challenges |
Some patents invalidated |
| 2020–2023 |
Ongoing discovery and pending motions |
Litigation continues |
Key Takeaways
- Purdue Pharma’s lawsuit against Alvogen focuses on patent rights for abuse-deterrent opioid formulations.
- The case involves complex issues of patent validity, infringement, and market exclusivity.
- Outcomes hinge on court rulings regarding patent strength and scope, impacting timing for generic market entry.
- The case reflects broader industry trends around patent enforcement, patent challenges, and the opioid market’s regulatory environment.
- The resolution remains pending, with potential implications for product innovation and litigation strategies in the pharmaceutical industry.
FAQs
1. What patents are involved in Purdue Pharma v. Alvogen?
The case involves U.S. Patent Nos. 8,657,241 and 9,219,376, related to abuse-deterrent formulations of opioids.
2. Has the court ruled on patent infringement yet?
Pending. The court has held hearings and issued rulings on patent validity, but no final judgment on infringement has been publicly reported.
3. Why did Purdue seek a preliminary injunction?
To prevent Alvogen from launching generic products until the patent issues are resolved.
4. What are Alvogen’s primary defenses?
Claims of patent invalidity due to obviousness and lack of novelty, and non-infringement.
5. How does this case influence the opioid market?
It exemplifies patent strategies to delay generic competition, affecting drug pricing and availability.
References
[1] U.S. District Court, District of New Jersey. Purdue Pharma L.P. v. Alvogen Pine Brook LLC, 1:15-cv-00784.
[2] U.S. Patent Nos. 8,657,241; 9,219,376.
[3] Court filings and rulings documented through PACER and public court records (2023).
